Photochemical Inactivation of Bacteria and HIV in Buffy‐Coat‐Derived Platelet Concentrates under Conditions That Preserve in vitro Platelet Function

Knutson, Folke; Alfonso, Ryan; Dupuis, Kent; Mayaudon, V.; Lin, Lily; Corash, Laurence; Högman, Claes F.

doi:10.1046/j.1423-0410.2000.7840209.x

Cited by 91 publications

(101 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 Previously reported studies have demonstrated that the PCT technology provides robust inactivation of viruses, bacteria, and leukocytes in platelet components. 5,8,9 Based on this clinical trial, pooled platelet components prepared with PCT and stored for up to 5 days offer the potential to reduce transfusion-associated infections and inactivate residual contaminating leukocytes using a processing system that is compatible with the current method of preparing therapeutic doses of buffy coat platelets.…”

Section: Discussionmentioning

confidence: 99%

“…11 Pooled platelet concentrates were leukoreduced by filtration followed by photochemical treatment (PCT) with 150 M S-59 and 3 J/cm 2 UVA treatment (Helinx Technology; Cerus Corporation, Concord, CA) for pathogen and leukocyte inactivation. 5,8,9 After PCT, pooled platelet concentrates were stored for up to 5 days before transfusion. PCT was used in place of ␥ irradiation for prevention of transfusion-associated graft-versus-host disease.…”

Section: Platelet Componentsmentioning

confidence: 99%

“…5,6 Preclinical studies have demonstrated inactivation of more than 10 6 infectious HIV particles, more than 10 5 infectious hepatitis B (HBV) and HCV particles, and a broad spectrum of gram-positive and gram-negative bacteria. 5,7,8 Furthermore, this process inactivates more than 10 5 contaminating T cells with effective inhibition of proliferation and complete suppression of leukocyte cytokine synthesis. 9,10 To utilize this technology in blood component processing, a device consisting of a series of closed interconnected plastic containers and a microprocessor-controlled UVA light source has been integrated into a system for preparation of therapeutic doses of platelets.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Rhenen

Gulliksson

Cazenave

et al. 2002

Blood

289

444

View full text Add to dashboard Cite

A nucleic acid-targeted photochemical treatment (PCT) using amotosalen HCl (S-59) and ultraviolet A (UVA) light was developed to inactivate viruses, bacteria, protozoa, and leukocytes in platelet components. We conducted a controlled, randomized, double-blinded trial in thrombocytopenic patients requiring repeated platelet transfusions for up to 56 days of support to evaluate the therapeutic efficacy and safety of platelet components prepared with the buffy coat method using this pathogen inactivation process. A total of 103 patients received one or more transfusions of either PCT test (311 transfusions) or conventional reference (256 transfusions) pooled, leukoreduced platelet components stored for up to 5 days before transfusion. More than 50% of the PCT platelet components were stored for 4 to 5 days prior to transfusion. The mean 1-hour corrected count increment for up to the first 8 test and reference transfusions was not statistically significantly different between treatment groups (13 100 ؎ 5400 vs 14 900 ؎ 6200, P ‫؍‬ .11). By longitudinal regression analysis for all transfusions, equal doses of test and reference components did not differ significantly with respect to the 1-hour (95% confidence interval [CI], ؊3.1 to 6.1 ؋ 10 9 / L, P ‫؍‬ .53) and 24-hour (95% CI, ؊1.3 to 6.5 ؋ 10 9 /L, P ‫؍‬ .19) posttransfusion platelet count. Platelet transfusion dose, pretransfusion storage duration, and patient size were significant covariates (P < .001) for posttransfusion platelet counts. Clinical hemostasis, hemorrhagic adverse events, and overall adverse events were not different between the treatment groups. Platelet components prepared with PCT offer the potential to further improve the safety of platelet transfusion using technology compatible with current methods to prepare buffy coat platelet components. (Blood. 2003;101: 2426-2433)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Platelet Componentsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Rhenen

Gulliksson

Cazenave

et al. 2002

Blood

289

444

View full text Add to dashboard Cite

show abstract

“…Reducing the risk even further may ultimately require alternative approaches, such as pathogen reduction. 15,[18][19][20] While the current culture systems have increased platelet safety, there are a number of costs: higher prices for platelets, 1-2% product loss from sampling and 12-30 hour delays in platelet product release, potentially affecting platelet availability. 21 It is hoped that these costs will be offset by the benefits of being able to extend platelet storage beyond the 5-day limit.…”

Section: Impact Of Bacterial Testingmentioning

confidence: 99%

Platelets: Testing, Dosing and the Storage Lesion—Recent Advances

Kaufman¹

2006

Hematology

View full text Add to dashboard Cite

The demand for platelet transfusions continues to grow. Several complementary approaches that may help meet this demand in the future are reviewed. First, platelet bacterial testing is beginning to allow the extension of platelet storage beyond 5 days. Studies are also underway aimed at better preserving viability and function during ex vivo platelet storage: additive solutions and other approaches are being developed to try to negate the "platelet storage lesion." Finally, new approaches to dosing platelets may help extend the limited supply.

show abstract

“…Starting in 1989, a series of research publications examined the utility of existing psoralens (8-MOP and AMT) and novel psoralens (amotosalen HCl) for the inactivation of infectious pathogens and leukocytes in platelet and plasma blood components. [27][28][29][30][31][32][33][34][35][36] Recently, a photochemical process using amotosalen HCl has received European approval for inactivation of infectious pathogens and leukocytes in platelet components. 37 This technology utilizes the novel psoralen compound amotosalen HCl, formerly known as S-59, and long wavelength ultraviolet light (UVA) to induce the formation of irreversible, covalent psoralen-nucleic acid adducts ( Figure 2).…”

Section: Risk Factors For Ta-gvhd and Current Technologymentioning

confidence: 99%

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Corash

Lin

2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood component transfusion therapy. Currently, cellular blood components for patients recognized at risk for TA-GVHD are irradiated prior to transfusion in order to prevent this complication. Considerable progress has been made in elucidating the pathophysiology of this highly morbid complication, but questions as to which patients are at risk and what is the most robust technology to prevent TA-GVHD remain. As new technologies for inactivating or modulating leukocyte function are introduced, the question of how to evaluate these technologies becomes relevant. Over the past two decades, a number of research groups have explored technology to inactivate infectious pathogens and leukocytes contaminating cellular blood components. Few clinicians have an in-depth understanding of the methods or the criteria for selection of how to approach new technologies for leukocyte inactivation with potential to replace current methods. This mini review focuses on the salient aspects of current and evolving technology for prevention of TA-GVHD.

show abstract

Photochemical Inactivation of Bacteria and HIV in Buffy‐Coat‐Derived Platelet Concentrates under Conditions That Preserve in vitro Platelet Function

Cited by 91 publications

References 22 publications

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

Platelets: Testing, Dosing and the Storage Lesion—Recent Advances

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Contact Info

Product

Resources

About